EE287

Epidemiologic and Economic Impact of COVID-19 Vaccination Among At-Risk Individuals and Individuals Aged ≥60 Years in Germany

Keya Joshi,[1] Michele Kohli,[2] Michael Maschio,[2] Amy Lee,[2] Kelly Fust,[2] Ekkehard Beck,[1] Nicolas Van de Velde,[1] Stefan Scholz,[3,*] Bernhard Ultsch[3]

[1]Moderna, Inc., Cambridge, MA, USA; [2]Quadrant Health Economics Inc., Cambridge, ON, Canada; [3]Moderna Germany GmbH, Munich, Germany
*Presenting author.

SUPPLEMENTARY MATERIAL

Supplementary Methods

- The model assumes that the Moderna fall 2023 vaccine would be administered to adults aged ≥60 years and at-risk adults aged 30 to 59 years between September and December 2023, with coverage and uptake similar to the 2021-2022 influenza vaccination in Germany[1,2]
- The size of the German population, by age, was obtained from the United Nations Department of Economic and Social Affairs[3]
- Based on published literature, 21% of the population aged 30 to 59 years was estimated to have had ≥1 chronic condition that increased the risk of severe COVID-19 outcomes[4]

Supplementary Figure 1. SEIR Model



Supplementary Figure 2. Infection Consequences Decision Tree



ICU, intensive care unit.

References

1. RKI. https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2022/Ausgaben/49_22.pdf?__blob=publicationFile
2. Paul-Ehrlich Institute. Seasonal Influenza 2021/2022. https://www.pei.de/EN/medicinal-products/vaccines-human/influenza-flu/preseasons/influenza-flu-season-2021-2022-content.html.
3. United Nations Department of Economic and Social Affairs PD. World Population Prospects 2022, Online Edition. Population by Single Age – Both Sexes 2022. https://population.un.org/wpp/Download/Standard/Population/
4. Holstiege J, et al. *BMC Public Health*. 2021;21:1769. doi:10.1186/s12889-021-11735-3.

Presented at ISPOR Europe; November 12-15, 2023; Copenhagen, Denmark